ESC Premium Access

Oral anticoagulation in atrial fibrillation patients at intermediate risk of stroke: a nationwide registry-based cohort (Atrial Fibrillation in Norway - AFNOR)

Congress Session

About the speaker

Doctor Mariam Anjum

Baerum Hospital, Baerum (Norway)
0 follower

4 more presentations in this session

Early Rhythm-Control Therapy in Patients with Atrial Fibrillation: A nationwide cohort study

Speaker: Doctor T. Chao (Taipei, TW)

Thumbnail

Risk of atrial fibrillation development of sodium-glucose co-transporter 2 inhibitor and thiazolidinedione treatment among patients with type 2 diabetes

Speaker: Assistant Professor Y. Kim (Gwangju, KR)

Thumbnail

Are the results of the RATE-AF trial reproducible in daily practice? Clinical outcomes with digoxin vs beta-blocker for heart rate control in permanent atrial fibrillation

Speaker: Professor L. Fauchier (Tours, FR)

Thumbnail

Low incidence of major complications after the first six hours post-atrial fibrillation ablation - same-day discharge safe and feasible in most patients

Speaker: Doctor A. Paul Nordin (Stockholm, SE)

Thumbnail

Access the full session

Clinical questions: management of patients with atrial fibrillation

Speakers: Doctor M. Anjum, Doctor T. Chao, Assistant Professor Y. Kim, Professor L. Fauchier, Doctor A. Paul Nordin
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

27 August 2021

ESC Premium Access

Heart failure as a complication of covid-19 infection: systematic review and meta-analysis

27 August 2021

ESC Premium Access

Additive prognostic value of cardiac biomarkers in patients with chronic obstructive pulmonary disease and heart failure

27 August 2021

This platform is supported by

logo Novo Nordisk